Not credible: A subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Ann Oncol 2007; 18 Suppl 3: pp 1-75)

Annals of Oncology

Volumn 18, Issue 9, 2007, Pages 1433-1435

  Coleman, Michel P ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; RITUXIMAB; TRASTUZUMAB;

CANCER MORTALITY; CANCER SURVIVAL; COMPARATIVE STUDY; DRUG INDUSTRY; DRUG RESEARCH; EARLY DIAGNOSIS; EDITORIAL; EUROPEAN UNION; FUNDING; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SPECIALIST; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME;

EID: 34548445564     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm363     Document Type: Editorial

References (24)

1. Wilking N, Jönsson B. A pan-European comparison regarding patient access to cancer drugs. Stockholm, Sweden, Karolinska Institutet and Stockholm School of Economics, 7 September 2005.
2. Coleman MP. New drugs and survival: Does the Karolinska report make sense? Cancer World 2006; September-October; 26-29.
3. Cancer United. BBC Radio 5, Wake up to Money. 0530h 19 October 2006.
4. Jönsson B, Wilking N. A global comparison regarding patent access to cancer drugs. Ann Oncol 2007; 18 (Suppl. 3): 1-74.
5. Berkson J, Gage RP. Calculation of survival rates for cancer. Proc Staff Meet Mayo Clinic 1950; 25: 270-286.
6. Coleman MP, Babb P, Damiecki P et al. Cancer survival trends in England and Wales 1971-1995: Deprivation and NHS Region. Series SMPS No. 61. London: The Stationery Office, 1999, pp 1-695.
7. Ederer F, Axtell LM, Cutler SJ. The relative survival: A statistical methodology. Natl Cancer Inst Monogr 1961; 6: 101-121.
8. Cutler SJ (Ed). International symposium on end results of cancer therapy. NCI Monograph 15. Bethesda MD National Cancer Institute 1964.
9. Micheli A, Baili P, Mugno E et al. Life expectancy and cancer survival in the EUROCARE-3 cancer registry areas. Ann Oncol 2003; 14 (Suppl 5): 28-40.
10. Grosclaude PC, Godet J, Arveux P et al. Survie des patients atteints de cancer en France: étude des registres du réseau FRANCIM. Lyon La Ligue contre le cancer; FRANCIM [French Cancer Registry Network], 2007.
11. Gatta G, Capocaccia R, Sant M et al. Understanding variations in colorectal cancer survival in Europe: A EUROCARE high-resolution study. Gut 2000; 47: 533-538.
12. EUROCARE Working Group. Publications from the EUROCARE study. EUROCARE Working Group, 8 June 2007; http://www.eurocare.it
13. IMS Oncology Analyzer - Europe. IMS Oncology, 6 June 2007; http://www.imsoncology.com/pages/onc_page_4_.5.html.
14. Ferlay J, Bray F, Pisani P et al. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0 IARC, 1 May 2006; http://www-dep.iarc.fr
15. Berrino F, Capocaccia R, Coleman MP et al. (eds). EUROCARE-3: The survival of cancer patients diagnosed in Europe during 1990-94. Ann Oncol 2003; 14 (Suppl 5): 1-155.
16. Wilking N, Jönsson B. The Debate on "New drugs and survival: Does the Karolinska report make sense?". Cancer World 2006; September-October: 30-35.
17. Richards MA. The Debate on "New drugs and survival: Does the Karolinska report make sense?". Cancer World 2006; September-October: 30-35.
18. Morgan G, Ward R, Barton M. The contributon of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (Roy Coll Radiol) 2004; 16: 549-560.
19. Sinha G. European Union creates its own "Critical Path". J Natl Cancer Inst 2007; 99: 832-833.
20. Fleming N. Cancer survival rates worst in western Europe. Daily Telegraph. Telegraph Media Group, London, 10 May 2007, p1, http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2007/05/10/ ncancer10.xml
21. Walsh F. Why France is so good at cancer care. BBC News, 16 May 2007; http://news.bbc.co.uk/2/hi/health/6660665.stm
22. Anon. Cancer treatment: Not just a question of costs. Lancet 2007; 369: 1665.
23. Friedberg M, Saffran B, Stinson TJ et al. Evaluation of conflict of interest in economic analyses at new drugs used in oncology. J Am Med Assoc 1999; 282: 1453-1457.
24. Lexchin J, Bero LA, Djulbegovic B et al. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. Br Med J 2003; 326: 1167-1170.